Introduction

The 2026 ASCO Annual Meeting brought what may be the most significant pancreatic cancer data in years: the phase 3 RASolute 302 trial, which showed that a RAS-targeted oral therapy roughly doubled overall survival compared with chemotherapy in previously treated metastatic disease. This is worth treating as a starting line rather than a finish line, since a great deal remains to be worked out about how best to target RAS, and how to combine RAS-directed therapy with everything else in the pancreatic cancer treatment toolkit, but the result itself is genuinely paradigm-shifting.

Understanding the Target: RAS Signaling in Pancreatic Cancer

RAS is a growth-control protein that cycles between an "on" state, signaling cell growth, and an "off" state. That cycling is normal biology; the problem in cancer is that mutations lock RAS in the "on" position, driving uncontrolled growth. The majority of pancreatic ductal adenocarcinoma (PDAC) tumors carry a RAS mutation, most commonly at G12, with G13 and Q61 occurring less frequently, but it's worth being precise about terminology here: even tumors without an identifiable RAS mutation can still show excessive RAS-driven signaling, so "RAS wild-type" doesn't necessarily mean RAS-independent, and there may be a broader role for RAS-targeted therapy than mutation status alone would suggest.

Daraxonrasib is an oral, RAS(ON) multi-selective inhibitor, meaning it targets the active-state conformation of RAS across multiple mutation variants and wild-type RAS alike, rather than being restricted to a single specific mutation the way some earlier RAS inhibitors (like the G12C-specific agents used in other cancers) are. Mechanistically, the drug prevents formation of the complex RAS normally forms with cyclophilin and RAF that drives downstream signaling.

RASolute 302: Trial Design and Results

RASolute 302 enrolled 500 patients with metastatic PDAC who had progressed on one prior line of standard chemotherapy (a fluoropyrimidine or gemcitabine-based combination). Patients were randomized to daraxonrasib 300 mg once daily (n=248) or investigator's choice of chemotherapy (n=252). Notably, RAS mutation testing was required for eligibility, but no specific RAS mutation type was required, and the trial included a cohort of RAS-unidentified or wild-type patients as well, though data in that subgroup is still maturing.

At a median follow-up of 8.5 months, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with chemotherapy, very nearly doubling survival (hazard ratio, 0.40; P<.0001). Progression-free survival was similarly improved. The survival benefit with daraxonrasib was seen across the board, including in patients with a G12 mutation specifically, where the separation between treatment arms was clear and did not require statistical fine print to appreciate.

Managing the Signature Toxicity: Rash

The tolerability story is just as important as the efficacy story here, because how well a drug is tolerated determines whether patients can actually stay on it long enough to benefit. Rash is the toxicity to plan for with daraxonrasib, and it is not a "wait and see" side effect, it should be anticipated and managed proactively, similar to how skin toxicity is managed with EGFR-targeted antibodies. Patients starting daraxonrasib should begin an antibiotic (doxycycline or minocycline) and a topical regimen at treatment initiation, not after a rash appears. Anecdotally, the rash tends to be most intense in the first four to six weeks and may taper afterward, which offers some flexibility in how aggressively to manage it as treatment continues.

Despite this, rash did not significantly compromise patients' ability to stay on treatment: about 17% of patients required a dose reduction because of rash, and discontinuation specifically due to rash was rare, just one patient in the daraxonrasib arm, compared with more frequent chemotherapy-related discontinuations in the control arm. The drug is available in both 100 mg and 150 mg tablet formulations, which should allow more flexible dose reduction (300 mg to 200 mg to 100 mg) than a single-tablet-strength approach would.

What Comes Next

RASolute 302 met all of its primary endpoints and supports a new standard of care for previously treated metastatic pancreatic cancer, but daraxonrasib's development program extends well beyond this result. A first-line study is enrolling, comparing chemotherapy plus daraxonrasib against chemotherapy alone and against daraxonrasib alone. An adjuvant study is also open, enrolling patients who have completed standard adjuvant therapy and randomizing them to daraxonrasib or observation. A related allele-specific G12D agent (zoldonrasib) from the same research program is being tested in first-line combinations as well, with some evidence that resistance to broad RAS inhibition may develop because a dominant allele-specific clone isn't being adequately targeted, meaning a paired broad-plus-allele-specific inhibitor strategy might ultimately prove more durable than either approach alone.

Several other companies are also developing RAS-targeted approaches beyond inhibition, including RAS-degrading agents, so this is very much an active and expanding area rather than a single-drug story. For a disease that has seen relatively little movement in systemic therapy for years, having RAS finally become a druggable, clinically meaningful target is a genuinely exciting development, and RAS-targeted therapy is likely to expand across the full spectrum of pancreatic cancer clinical presentations in the coming years, whether as monotherapy or in rational combinations.

Two Additional Findings Worth Knowing

Two other presentations, while less headline-grabbing, are practical enough to affect care sooner. The CHALLENGE trial, first reported several years ago, tested a structured exercise program after adjuvant therapy for colorectal cancer and found improved overall and disease-free survival; a new cost-utility analysis presented this year found that despite upfront program costs, the intervention produced net cost savings by reducing recurrence and its downstream costs, on top of its already-established survival benefit. This strengthens the case for offering structured exercise programs as a standard part of colorectal cancer survivorship care wherever feasible.

Separately, a study looked at whether patients with dMMR colorectal cancer who achieve a complete clinical response to chemoimmunotherapy without surgery benefit from continuing maintenance immunotherapy versus simply being observed. Survival outcomes were similar between the two approaches, but immune-related toxicity, including some grade 3 events and endocrine toxicities that can be long-lasting, was meaningfully higher with continued maintenance therapy. For patients who have a thoroughly confirmed complete clinical response, observation alone appears to be the better risk-benefit choice, though this does require a genuine shift in mindset for both patients and clinicians accustomed to continuing treatment as long as it's tolerated.

For Patients

For people with metastatic pancreatic cancer whose disease has progressed after one round of chemotherapy, a new oral drug called daraxonrasib nearly doubled survival compared with switching to a different chemotherapy in a large clinical trial, a genuinely significant advance for a disease that has had very few effective treatment options. The main side effect to expect is a skin rash, which your care team should help you manage proactively from the start of treatment, typically with an antibiotic and a topical skin treatment, rather than waiting for it to become severe.

For people with colorectal cancer who have finished adjuvant chemotherapy, a structured exercise program has been shown to improve survival and, according to new data, may actually save money for the healthcare system by reducing costly cancer recurrences, making a good case for asking your care team about exercise programs during recovery.

For people with a specific type of colorectal cancer (dMMR) who have had a complete response to chemotherapy and immunotherapy without needing surgery, continuing immunotherapy afterward does not appear to improve survival compared with careful monitoring alone, but it does increase the risk of immune-related side effects, some of which can be long-lasting.

Key Takeaways

  • RASolute 302 showed daraxonrasib nearly doubled median overall survival (13.2 vs 6.7 months; HR, 0.40; P<.0001) compared with chemotherapy in previously treated metastatic pancreatic cancer, supporting a new standard of care.

  • Rash is daraxonrasib's signature toxicity and should be managed proactively from treatment initiation with prophylactic antibiotics and topical therapy; despite this, discontinuation specifically due to rash was rare.

  • Daraxonrasib's development program extends to first-line combinations, an adjuvant setting trial, and allele-specific companion agents, reflecting a broader RAS-targeting strategy still very much in progress.

  • A structured exercise program after adjuvant colorectal cancer therapy (CHALLENGE trial) appears to be cost-saving in addition to improving survival; for dMMR colorectal cancer patients with a confirmed complete clinical response, observation alone appears preferable to continued maintenance immunotherapy given similar survival but higher toxicity with continued treatment.

References

  1. Wolpin BM, et al. RASolute 302: a randomized, phase 3 trial of daraxonrasib versus investigator's choice of chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma. Presented at: 2026 ASCO Annual Meeting Plenary Session (Abstract LBA5); simultaneously published in the New England Journal of Medicine.

  2. Presented at: 2026 ASCO Annual Meeting. CHALLENGE trial: cost-utility analysis of a structured exercise program after adjuvant therapy for colorectal cancer.

  3. Presented at: 2026 ASCO Annual Meeting. Observation versus maintenance immunotherapy after complete clinical response in dMMR colorectal cancer treated with chemoimmunotherapy without surgery.